Imunon, Inc.IMNN
Price (close)
$1.35
Market cap
$6.3M
P/E
—
Revenue (TTM)
—
Net income
-$14.7M
Dividend yield
—
1-year total return
-74.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Imunon, Inc. does.
of the statements contained in this Annual Report on Form 10-K (“Annual Report”) are forward-looking and constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning
of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $500,000 | $500,000 | $500,000 | — | — | — |
| Net income | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | -$14.5M |
| Free cash flow | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M |
More on IMNN.
- Imunon, Inc. summary
- Imunon, Inc. financial statements
- Imunon, Inc. key metrics
- Imunon, Inc. health scores and style box
- Imunon, Inc. earnings
- Imunon, Inc. dividends
- Imunon, Inc. valuation
- Imunon, Inc. ownership and insiders
- Imunon, Inc. peers
Figures from Imunon, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.